Annovis Bio reports Q1 EPS (72c), consensus (80c)

“The first quarter proved to be pivotal for our company as we continued to wind down our two recent clinical trials – Phase III in Parkinson’s and Phase II/III in Alzheimer’s. For our PD study, which concluded late last year, diligent efforts are underway to meticulously prepare the data, with expected delivery of topline results in June of this year. For the AD study, we successfully cleaned the data and were proud to announce cognitive improvements as measured by ADAS-Cog 11 in patients with early AD, showing us a pathway for continued clinical development of buntanetap. We extend our heartfelt gratitude to the patients and their families whose contribution was the driving force of our research aimed to bring new treatments to the market,” said Maria Maccecchini, Ph.D., Annovis Founder, President, and CEO